DiaMedica Therapeutics (DMAC) Liabilities and Shareholders Equity (2017 - 2026)

DiaMedica Therapeutics' Liabilities and Shareholders Equity history runs 10 years deep, the most recent figure standing at $53.1 million for Q1 2026.

• On a quarterly basis, Liabilities and Shareholders Equity rose 36.7% year-over-year to $53.1 million in Q1 2026; TTM through Mar 2026 was $203.0 million, a 4.36% increase from a year earlier, with the FY2025 full-year figure at $61.4 million, up 32.42% from the prior year.
• Liabilities and Shareholders Equity retreated to $53.1 million in Q1 2026 per DMAC's latest filing, from $61.4 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $62.0 million in Q2 2023 and bottomed at $30.2 million in Q1 2023.
• The 5-year median for Liabilities and Shareholders Equity is $49.3 million (2024), against an average of $47.3 million.
• Across the five-year window, Liabilities and Shareholders Equity surged 80.3% in 2022 and tumbled 44.59% in 2025, its largest moves.
• Year by year, Liabilities and Shareholders Equity stood at $34.4 million in 2022, then surged by 57.46% to $54.2 million in 2023, then declined by 14.43% to $46.3 million in 2024, then soared by 32.42% to $61.4 million in 2025, then fell by 13.51% to $53.1 million in 2026.
• Per Business Quant, the three latest DMAC Liabilities and Shareholders Equity figures stand at $53.1 million (Q1 2026), $61.4 million (Q4 2025), and $57.0 million (Q3 2025).